Aztreonam–avibactam versus meropenem for the treatment of serious infections caused by Gram-negative bacteria (REVISIT): a descriptive, multinational, open-label, phase 3, randomised trialYehuda Carmeli, Surbhi Malhotra‐Kumar, Herman Goossens et al.|The Lancet Infectious Diseases|2024Cited by 98